In this article, I’ll be looking once again at German company Evotec (NASDAQ:EVO) (OTCPK:EVOTF) – a business in the drug ...

Evotec SE (NASDAQ:EVO – Get Free Report) gapped up before the market opened on Thursday . The stock had previously closed at $4.16, but opened at $4.32. Evotec shares last traded at $4.29, with a ...

Halozyme provides subcutaneous drug delivery solutions, with several major new products recently approved. Click here to find ...

German stocks are a bit subdued Tuesday morning with investors making cautious moves amid a lack of significant triggers. Data on ...

Shares in Evotec rose after the company said Thursday that it received a takeover offer from U.S. biotechnology company Halozyme Therapeutics for about 2 billion euros ($2.11 billion). Shares ...

(RTTNews) - Novo Nordisk and Evotec have selected three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center for development ...

In this article, we are going to take a look at where Evotec SE (NASDAQ:EVO) stands against the other German stocks. In Germany, the economic growth is based on industry. According to Deutschland ...

LAB eN 2, the drug discovery accelerator launched by Evotec and Novo Nordisk in September 2023, has unveiled its first three projects and launched an expansion featuring five new academic partners.

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic ...

Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Bristol-Myers Squibb's Celgene unit has clearly been impressed by progress in its four-year-old alliance with Evotec on protein degradation. It's just paid $200 million to extend the partnership ...